Satellos concludes MAD cohort enrolment for Phase I trial of SAT-3247
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...
The American Journal of Managed Care3d
Ifetroban Improves Heart Function in DMD
There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...
Independent Record6d
'The Life of Riley': Helena mother's book chronicles family's battle with Duchenne muscular dystrophy
Despite the obstacles, Riley Herrera had a life filled with family, sports, travel, faith and hope before his death on Nov.
The EMBO Journal8d
Type-2 innate signals are dispensable for skeletal muscle regeneration and pathology linked to Duchenne muscular dystrophy
Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...
Morningstar7d
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
Patients with DMD slowly lose muscle function ... Cardiovascular Measures of All-Cause Mortality in Duchenne Muscular Dystrophy. Circ Heart Fail. 2023 Aug;16(8):e010040. doi: 10.1161/CIRCHEARTFAILURE.
Nasdaq8d
Entrada Therapeutics Authorizes Phase 1/2 Clinical Trial for ENTR-601-44 to Treat Duchenne Muscular Dystrophy, On Track for Q2 2025 Initiation
Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025 ... significant plasma concentration, muscle concentration and exon skipping.